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Abstract
Background: Access to medicines in developing countries continues to be a significant problem due to lack of
insurance and lack of affordability. Chronic Myeloid Leukemia (CML), a rare disease, can be treated effectively,
but the pharmaceutical treatment available (imatinib) is costly and unaffordable by most patients. GIPAP, is a
programme set up between a manufacturer and an NGO to provide free treatment to eligible CML patients in
80 countries worldwide.
Objectives: To discuss the socio-economic and demographic characteristics of patients participating in GIPAP;
to research the impact GIPAP is having on health outcomes (survival) of assistance-eligible CML patients; and to
discuss the determinants of such outcomes and whether there are any variations according to socio-economic,
demographic, or geographical criteria.
Methods: Data for 13,568 patients across 15 countries, available quarterly, were analysed over the 2005-2007
period. Ordered Probit panel data analysis was used to analyze the determinants of a patient's progress in terms
of participation in the programme. Four waves of patients entering quarterly in 2005 were used to evaluate patient
survival over the sample period.
Results: All patients in the sample are eligible to receive treatment provided they report to a facility quarterly.
62.3% of patients were male and 37.7% female. The majority (84.4%) entered during the chronic phase of the
disease and their average age was 38.4 years. Having controlled for age, location and occupation, the analysis
showed that patients were significantly much more likely to move towards a better health state after receiving
treatment irrespective of their disease stage at the point of entry to the program (OR = 30.5, α = 1%); and that
the larger the gap between diagnosis and approval for participation in the program, the more likely it is that
patients' condition deteriorates (OR = 0.995, α = 1%), due to absence of treatment. Regressions to account for
the effect of large countries (India, China, Pakistan) did not show any important differences when compared to
the remaining countries in the sample. Survival analysis shows that at least 66 percent of all patients that entered
the program in 2005 were alive and active by the end of 2007.
Conclusions:  GIPAP has a significant positive effect on patient access to important medicines for a life
threatening condition such as CML. It impacts both the progress and phase of the disease and leads to a high
survival rate. Overall, it sets a good example for access to treatment in developing countries, where such
programmes can substitute or complement local efforts to provide care to eligible patients.
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Background and objectives
Patients suffering from life-threatening conditions in
developing countries are often unable to access medicines
that are critical for their treatment and survival. The high
cost of medicines in relation to disposable income, low
overall income and lack of health insurance coverage are
determining factors of poor access, together with infre-
quent availability and poor quality [1]. It is estimated that
in a number of transition countries and most developing
nations, more than 80 per cent of pharmaceuticals are
purchased out-of-pocket through both formal and infor-
mal means [2,3]. Beyond access to medicines, there are
significant barriers to accessing services, including lack of
available infrastructure, lack of diagnostic capabilities,
and poor transport options, among others.
Chronic Myeloid Leukemia (CML) is a rare, life threaten-
ing condition affecting between one and two people per
100,000 annually. CML represents 15-20% of all cases of
adult leukemia in Western societies. Frontline treatment
of CML involves the use of Imatinib (Glivec®) (Appendix
1, Note 1). The beta crystal form of Imatinib has revolu-
tionized the treatment and continued management of
CML through precise molecular targeting; it appears to be
more effective than Interferon-alpha (IFN-α) in terms of
cytogenetic response (CR) and progression-free survival
(PFS), with fewer side effects for patients in the chronic
phase [4] and is also cost-effective compared to alternative
therapy [5]. Studies have shown that, over a period of 5
years, a patient in the accelerated phase of CML will, on
average, accrue an additional 2.09 Quality Adjusted Life
Years (QALYs) with imatinib compared with conven-
tional therapy, while patients in the blast-crisis phase will
accrue an additional 0.58 QALYs compared with conven-
tional therapy [6].
The Glivec International Patient Assistance Program
(GIPAP) is a program set up by a manufacturer (Novartis)
in partnership with an NGO (The Max Foundation - TMF)
in collaboration with other NGOs such as the China Char-
ity Foundation and Axios International, to facilitate access
to and distribution of imatinib directly to patients
through their providers. GIPAP aims to fill the gaps of
imperfect access to eligible patients in developing coun-
tries that cannot afford this costly treatment [7]. Under
the program, the manufacturer provides the drug at no
cost directly to eligible patients identified and selected by
TMF in participating countries. This is not the only global
partnership that helps provide important medicines to
people who cannot afford them in developing countries
[8,9]. The International Trachoma Initiative (ITI) helps
the implementation of plans to eliminate blinding tra-
choma [10]. The Mectizan partnership, involving a phar-
maceutical manufacturer (MSD), the World Bank,
governments and NGOs was set up in order to provide
ivermectin to patients in developing countries [11]. The
Accelerated Access Initiative (AAI) involves seven
research-based pharmaceutical manufacturers and five
United Nations partners aiming to provide better access to
anti-retroviral (ARV) drugs in developing countries; by the
end of December 2005, more than 716,000 people living
with HIV/AIDS in developing countries were receiving
treatment with at least one ARV medicine provided by the
AAI [12]. The World Health Organization has set up
guidelines which must be followed in these cases. GIPAP
also complies with these guidelines.
Currently, 80 countries worldwide take part in GIPAP and
the total number of active CML patients benefiting from
this initiative reaches 18,000 worldwide. Table 1 shows
the breakdown of participating regions and the CML
active patients per region.
In many participating countries, particularly those in sub-
Saharan Africa, GIPAP is the only source of available treat-
ment for CML, as there is no state health insurance and
very few people can afford private health insurance or the
out-of-pocket expense to acquire the needed medication.
As a result, GIPAP may often cover all patients diagnosed
with the condition irrespective of the type of facility they
are diagnosed in (Appendix 1, Note 2). There are no
restrictions in the number of patients eligible for GIPAP in
Table 1: Geographical distribution of GIPAP active1 participating patients, 2007
Continent Population2 Number of active CML patients % of population active
Asia 3,461,233,811 14,927 0.0004%
Africa 643,500,700 1,201 0.0002%
Latin America 371,975,205 1,370 0.0004%
Europe 245,085,256 509 0.0002%
Oceania 839,000 7 0.0008%
Total 4,722,633,972 18,004
Note: 1 If the number of non-active patients is added, the total number of patients participating in the program reaches 26,532.
2 Population figures are related to participating countries only.
Source: The authors from the GIPAP database.Globalization and Health 2009, 5:19 http://www.globalizationandhealth.com/content/5/1/19
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any participating country and, as this is a program requir-
ing significant physician input, new patients are enrolled
as long as a qualified physician assumes responsibility for
them. In countries such as Argentina and Chile, the pro-
gram is supplementary to state insurance coverage, the lat-
ter being limited only to certain population groups (e.g.
government officials).
In order to administer imatinib to eligible patients, the
manufacturer identifies the appropriate medical centres
and physicians and supplies the drug to these centers.
These centres have been certified to comply with mini-
mum services to CML patients. Reports for each patient
are filled in quarterly by physicians and sent to TMF's
headquarters. A requirement for a physician to participate
in the programme is that s/he has an internet connection.
TMF conducts socio-economic evaluations of patients,
guides physicians through the patient evaluation process,
and provides emotional support, information and referral
assistance to patients, their families and care givers. It also
monitors patients to support the highest standard of
patient care, helps identify and qualify eligible medical
centers and physicians worldwide, and protects confiden-
tial patient information and data received during the
implementation of the program. A program with such
broad geographical expanse cannot work exactly in the
same way in all regions or countries. Thus, the operational
requirements of GIPAP vary from country to country or
region to region.
While GIPAP has been in operation for several years, thus
far, assessment of the impact it is having on CML patients
in developing countries has at best been anecdotal or
relied on individual physician opinions [13]. In this paper
we aim to, first, identify and discuss the socio-economic
and demographic characteristics of the patients participat-
ing in GIPAP, and, second, to analyze the impact the pro-
gram is having on health outcomes of CML-diagnosed
patients, discuss the determinants of such outcomes and
whether there are any variations according to socio-eco-
nomic, demographic, or geographical criteria. In doing so,
the paper also discusses the policy implications regarding
access to medicines in developing countries. Section 2 dis-
cusses the methodology employed in the paper; section 3
presents and section 4 discusses the results; finally, section
5 draws the main conclusions.
Data and Methods
Data
In order to address the above objectives, we focused on
CML using data collected by TMF as part of its global remit
to implement GIPAP. The manufacturer establishes socio-
economic criteria modeled on the World Health Organi-
zation guidelines for charitable donation programs as
well as medical criteria determining patient eligibility for
GIPAP, while TMF reviews patient applications for partic-
ipation in the program and collects data and information
on each patient in the program based on physician
records and assessment. As a result, TMF has exclusive
responsibility and oversight in setting up, running and
monitoring the program (Appendix 1, Note 3).
Patient eligibility is determined primarily on the basis of
diagnosis as well as income/socioeconomic status, as fol-
lows: (a) GIPAP helps patients who are properly diag-
nosed with Philadelphia chromosome-positive chronic
myeloid leukemia (Ph+ CML) and patients with c-Kit
(CD117)-positive inoperable and/or metastatic malig-
nant gastrointestinal stromal tumors (GISTs) (Appendix
1, Note 4); and (b) GIPAP provides assistance to patients
who are not insured or reimbursed, cannot pay for treat-
ment privately, and live in countries that have minimal
reimbursement capabilities for their condition. Based on
these criteria, it is possible that GIPAP covers all those
diagnosed with CML in certain countries because of their
low income level.
Data were extracted from the TMF database covering the
period from the beginning of 2005 to the end of 2007 on
a quarterly basis ensuring that all patients had first entered
in the first quarter of 2005 or later. Thus, the study period
comprised 12 quarters. Patients that entered the program
before this date were excluded as the objective was to
study patients from the moment of their entry in the pro-
gram. The study included 15 countries in the analysis,
namely, Kenya, Nigeria, South Africa and Sudan from
Africa; Argentina, Chile, El Salvador and Mexico from
Latin America; Russia and Georgia from Europe; China,
India, Malaysia, Pakistan and Thailand from Asia. In the
Chinese context, each of China's provinces and municipal
entities has its own healthcare infrastructure. This necessi-
tates varying reimbursement schemes for Imatinib,
including shared contribution and co-pay models.
Country selection was based on geography, ensuring rep-
resentation from all continents where the program oper-
ates, the size of eligible population, program penetration
(percentage of participants in total patient population)
and health insurance program availability for some seg-
ments of the population. This resulted in the total number
of patients being 13,568 across the selected countries and
for the study period (Appendix 1, Note 5). Of these
patients there was no information about the initial phase
for only 3 patients and no information about the latest
phase for 20 patients. When taking into account the time
dimension, the total sample size was N = 66,681 observa-
tions during the study period 2005-2007. The sample
includes the largest GIPAP participant (India), other large
Asian countries (Pakistan, Thailand, Malaysia and China),
countries with some health insurance coverage for smallGlobalization and Health 2009, 5:19 http://www.globalizationandhealth.com/content/5/1/19
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segments of the population, (Russia, Argentina, Chile,
Mexico and Georgia), African countries with large popula-
tions (South Africa, Nigeria, Kenya and Sudan) and repre-
sentative Latin American countries such as Mexico,
Argentina and El Salvador.
TMF collects feedback from the participating physicians
electronically and on a regular basis; in addition patients
must be medically re-approved on average four times per
year in order to continue receiving treatment. As a result,
the frequency of data is quarterly. If a patient does not
present himself for their quarterly review, they are consid-
ered as "closed" or non-active, but they can be re-instated
in the program if contact with them is re-established.
Aside from monitoring eligible patients closely, this also
enables longitudinal analysis.
The patient-related data are sent from local GIPAP partic-
ipating physicians to the central database quarterly. The
data are stored in the central system at TMF headquarters
in Seattle. All data are anonymous and are uniquely iden-
tified by a code number. The data for this study were
accessed through the IT services at TMF, by country,
patient and other demographic characteristics. The unit of
analysis is always the patient.
Dependent Variables
The variable used as a proxy of patient performance
within GIPAP is a patient's current phase (curphase). Cur-
rent phase refers to one of the different phases a patient
may be in: Blast Crisis, Accelerated, Chronic or Remission.
A number was assigned to each phase: 1 for blast crisis, 2
for accelerated phase, 3 for chronic phase and 4 for remis-
sion, making this a discrete variable. In this categorization
the lowest number represents the worst possible clinical
state (blast crisis) and the highest number denotes the
best possible clinical state (remission).
Explanatory Variables
A number of explanatory variables were included in the
analysis, as follows: Origphase refers to the patient's health
or clinical state upon their admission to the program; it
can therefore be categorized as 1 for blast crisis, 2 for
accelerated phase and 3 for chronic phase. The study
period commenced in quarter 1, 2005, and all patients
active before that date are excluded from the analysis.
Age at approval is the age of the patient at the time of their
admission to the program. Quarter (1-12) refers to time,
starting with the first quarter of 2005 till the fourth quar-
ter of 2007, a total of 12 quarters. This is a control variable
used to capture unobserved heterogeneity, factors which
change over time and cannot be included in the vector of
explanatory variables and enables to control for natural
changes in patient outcomes over time. There are many
factors that tend to change over time and the inclusion of
a time variable eliminates this effect. Gender is a dummy
variable, which takes the value of 0 for men and 1 for
women. Gap  denotes the number of months from the
confirmation of the diagnosis date to the approval of par-
ticipation in GIPAP.
Close indicates whether a patient has been closed at least
once over the period he has been participating in the pro-
gram. It is a binary variable taking the value of 0 and 1, 0
indicating that the patient has never been closed, 1 indi-
cating that patient has been closed at least once. A patient
is considered to be closed when s/he has not reported for
treatment to his/her designated centre for 1 quarter. Con-
sequently, this does not refer to the present status of the
patient as active or closed. It is used as a control variable
to capture unobserved characteristics of a patient who has
not always been present in the program. Patients may be
classified as "closed" for a variety of reasons, including (a)
inability to keep track of the patient, (b) the patient not
making the journey to the clinic where treatment takes
place, (c) the patient not showing up on the specified day
of their treatment, (d) inability to contact the patient, (e)
becoming ineligible to receive treatment through GIPAP
and (f) death. It is also possible that individual patients
may be "closed" more than once and re-appear in the
database, as patient participation depends on receipt of
treatment and monitoring on a quarterly basis. With the
exception of death, none of these reasons prevent patients
from re-entering the program in the next period once they
show up for their treatment. Thus, closures are a source of
potential bias in the data but they by no means imply that
the patient is deceased. Whereas patients who were closed
but re-entered the program did not die, for those who do
not re-appear in the dataset till the end of the study period
we cannot be certain about their status. This is a limitation
of the available data. Overall, there does not appear to be
any seasonal effect in the number of closed cases.
Ins is a dummy variable, taking into account whether a
country offers universal health insurance coverage to part
of its population. Four countries (The Russian Federation,
Argentina, Chile and Georgia) offer universal health
insurance coverage - although by no means comprehen-
sive - to their population, whereas all other study coun-
tries do not. Although this does not apply to the GIPAP-
eligible population, as the latter is selected based on ina-
bility to pay, this variable is used as a control to explain
any heterogeneity in the data. For instance, it could be
argued that the presence of universal health insurance
indicates better features of the health system as a whole.
Health planning and improved geographical access could
be part of a program which includes health insurance for
a significant part of the population.
In addition, 14 country dummies are included, one for
each country, in order to control for any country-specificGlobalization and Health 2009, 5:19 http://www.globalizationandhealth.com/content/5/1/19
Page 5 of 13
(page number not for citation purposes)
effects as well as evaluate how the program compares
across countries. Finally, 13 dummy variables have been
introduced to identify patient occupation: Undefined, agri-
culture,  business,  education,  government,  health and social
work,  manufacturing,  other,  retired,  self employed,  student,
transport and unemployed. Profession also captures other,
unobserved patient characteristics, such as education,
medical sophistication and lifestyle. Table 2 presents all
variables included in the analysis and their definition.
Model Specification
Based on the discussion in the previous section, the model
that is considered for empirical analysis has the following
specification:
Curphase quarter origphase ins ageat it i it it it =++ + + + bbb b b b 01 2 3 4 a approval gender
gap close CountryDummy
it it
it it it
+
++ + +
b
bb b
5
67 8 b be 9OccupationDummyit it +
(1)
Table 2: Variables and definitions
Variable Mean Std. Dev.
Quarter Quarter (time). Indicates the number of quarters a patient has been participating in GIPAP 8.347 2.939
Origphase Original Phase of Patient: 1 for Blast Crisis, 2 for Accelerated, 3 for Chronic, 4 for Remission 2.821 0.488
Curphase Current Phase of the Patient: 1 for Blast Crisis, 2 for Accelerated, 3 for Chronic, 4 for Remission 2.924 0.554
Ins Dummy variable. Indicates whether there is universal health insurance coverage or not; 1 for Argentina, 
Chile, Georgia and Russia, 0 for the other countries.
0.039 0.193
Ageatapproval Age of the patient at his or her approval for participation in GIPAP 38.443 14.147
Gender Gender. Dummy variable; 0 for male, 1 for female 0.372 0.483
Gap Time gap between Diagnosis and Approval. It is the difference in months between the date of diagnosis of 
the patient suffering from CML and the date of approval for participation in GIPAP
4.617 8.997
Close Dummy variable. Indicates whether a patient is considered closed or not. 0 for not closed, 1 for closed. 0.056 0.231
Argentina 0.007 0.083
Chile 0.012 0.109
China 0.160 0.367
El Salvador 0.004 0.067
Georgia 0.008 0.086
India 0.520 0.500
Kenya 0.008 0.089
Malaysia 0.038 0.191
Mexico 0.028 0.165
Nigeria 0.009 0.092
Pakistan 0.103 0.303
Russia 0.012 0.110
South Africa 0.022 0.145
Sudan 0.026 0.158
Thailand 0.045 0.207
Undefined 0.068 0.252
Agriculture 0.229 0.420
Business 0.044 0.206
Education 0.019 0.136
Government 0.035 0.183
Health-Social 0.011 0.104
Hospitality 0.006 0.077
Manufacturing 0.040 0.195
Other 0.291 0.454
Retired 0.039 0.193
Self Employed 0.085 0.279
Student 0.029 0.168
Transport 0.013 0.115
Unemployed 0.091 0.288
Source: Authors' compilations from GIPAP database.Globalization and Health 2009, 5:19 http://www.globalizationandhealth.com/content/5/1/19
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Equation (1) has current phase as the dependent variable.
The values assigned to the current phase increase as the
outlook for the condition improves.
Estimation Method
In order to assess the effect GIPAP is having on CML
patients, both descriptive and econometric analysis are
pursued.
Descriptive statistics show the distribution of patients,
their phase from the moment they are accepted in the pro-
gram and an understanding of demographics. These also
show how characteristics change after entering the pro-
gram.
Panel data are used to conduct the econometric analysis.
The use of panel data is justified because it controls for
unobserved heterogeneity across individuals. The nature
of the patient-specific data allows the reasonable assump-
tion to be made that unobserved heterogeneity is uncorre-
lated with the included variables.
In this analysis, the special (ordinal) nature of the
dependent variable dictates the use of the ordered model.
A Panel Data Ordered Probit (OP) model is therefore used
in this case, as the dependent variable is not continuous.
Discrete values are assigned to different groups of obser-
vations, which change as patients' reported health state
changes. The OP model is preferable to the Ordinary Least
Squares (OLS) model because in the latter the variance of
the error term is not constant and is dependent upon the
explanatory variables [14]. The dependent variable is thus
ordered in such a way that imposes the use of the OP
model: An OP model treats differences between discrete
outcomes as constant [15]. In this model, the dependent
variable has a logical ordering. Current phase is ordered in
a logical sequence, depending on the severity of the dis-
ease, assigning different values to the different phases: 1
for blast crisis, 2 for accelerated phase, 3 for chronic phase
and 4 for remission, as identified in the literature. The
order assigns an increasing number for a better condition.
The odds ratio (OR) shows the probability of the patient
moving to a higher phase, over the probability of the
patient moving to a lower phase. In other words, the odds
ratio shows, for a unit change in the regressor, the odds of
a higher phase compared to a lower phase are changed by
a factor of the independent variable, other things being
equal.
Survival analysis
The study period and the longitudinal nature of the data
enables the assessment of the number of patients that
remained active up to 3 years after they first entered the
program (2005 - 2007). The definition of "active patients"
means that these patients continue to be registered in the
program and benefit from the treatment provided. Conse-
quently, this enables the measurement of survival at indi-
vidual patient level. In order to examine this, 4 waves of
new patients were isolated and studied, each wave enter-
ing quarterly in 2005. By following these patients through
to the end of the study period, it was possible to calculate
how many would benefit from GIPAP and observe the
attrition rate over three years. A survival rate was calcu-
lated as the ratio of those continuing to receive medica-
tion over the total number of patients that entered
originally.
Results
Descriptive Statistics
A summary of the descriptive statistics from the 15 study
countries is shown in Table 3. Of all participating patients,
62.3% are male. This is consistent with findings in other
settings that CML is a disease affecting men more fre-
quently than women. According to the National Cancer
Institute, CML affects 1.9 per 100,000 men and 1.1 per
100,000 women in the United States. The average age at
diagnosis in this study is 38.7 years, which is significantly
lower than similar patient cohorts in developed countries.
In the United States the average age at diagnosis over the
2001-2005 period was 66 years [16]. The dominant age
group in the study is age band 31-40 years (26.9%), fol-
lowed by 41-50 years (21.5%) and 21-30 years (20.5%).
At the time of initial diagnosis, 11,414 patients (84.14%)
were in the chronic phase, 1,229 (9.05%) were at the
accelerated phase and 923 (6.8%) were in blast crisis. No
patients enter GIPAP in the "remission" phase; patients in
remission reach that stage after receiving treatment.
Results of the Econometric Analysis
In order to account for the factors that determine the
progress of a patient diagnosed with CML, an Ordered
Probit panel data econometric model was estimated. The
panel identifier is the individual patient, as there exist
multiple observations for each patient at different points
in time. Following the model in equation (1), the depend-
ent variable was the current health state of the patient
such that the higher the number assigned to the current
state, the better the patient's overall condition or outlook.
The explanatory variables included different socio-eco-
nomic factors and demographics.
The original phase is positively and significantly associ-
ated with the current phase (OR = 30.5, α = 1%), indicat-
ing that patients classified as chronic in the original phase
were significantly much more likely to improve over time
(more likely to move towards a better health state); com-
parable effects could be seen for those patients in the
accelerated phase or blast crisis in the original phase. This
is consistent with expectations and the results shown in
the previous section, as patients whose initial conditionGlobalization and Health 2009, 5:19 http://www.globalizationandhealth.com/content/5/1/19
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was better are expected, on average, to be doing better at
later stages, once they enroll on the program. This also
suggests that, overall, the program contributes to patient
health improvement.
Patient age at approval is not statistically significant and
the OR is very close to 1. Results for gender show that this
variable is not statistically significant either. The time gap
between diagnosis and approval for entry into the pro-
gram is statistically significant. The larger the gap between
diagnosis and approval for GIPAP participation, the more
likely it is that the patient's condition deteriorates (OR =
0.995, α = 1%). This is explained by the fact that during
this time gap most patients would not have access to treat-
ment. As a result, shortening this gap over time may have
contributed to fast access to medical treatment by eligible
patients.
Table 3: Summary Statistics at Patient Level, 2005 - 2007
Participants (Total) 13,568
Average Age (years) 38.69
Average Time Gap between Diagnosis and Approval (months) 4.61
Age Group No. of patients No. of observations
0-20 1,332 9.82% 6474 9.71%
21-30 2,786 20.53% 13,970 20.95%
31-40 3,646 26.87% 18,273 27.40%
41-50 2,914 21.48% 14,191 21.28%
51-60 1,895 13.97% 9,185 13.77%
61-70 758 5.59% 3594 5.39%
71+ 237 1.75% 994 1.49%
Total 13,568 100.00% 66,681 100.00%
Gender
No. of patients No. of observations
Male 8,453 62.30% 41,873 62.80%
Female 5,115 37.70% 24,808 37.20%
Total 13,568 100.00% 66,681 100.00%
Original Phase
No. of patients No. of observations
Chronic 11,414 84.14% 57,728 86.57%
Accelerated 1,228 9.05% 5,958 8.94%
Blast Crisis 923 6.80% 2,995 4.49%
Total 13565 100.00% 66,681 100.00%
Current Phase
No. of patients1 No. of observations
Chronic N/A 54,192 81.27%
Accelerated 4,587 6.88%
Blast Crisis 2,794 4.19%
Remission 5,108 7.66%
Total 66,681 100.00%
Status
No. of patients1 No. of observations
Closed N/A 3,734 5.60%
Active 62,947 94.40%
Total 66,681 100.00%
Note: 1 Although we do have data at patient level, we cannot report summary statistics here, as this changes per patient over time. Thus, statistics 
are only reported per observation, not per patient.
Source: Authors' compilations from GIPAP database.Globalization and Health 2009, 5:19 http://www.globalizationandhealth.com/content/5/1/19
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The insurance variable does not yield statistically signifi-
cant results, which is expected, as GIPAP participation is
contingent on patients not having insurance coverage.
Insurance was used as a control variable to take into
account any unexplained heterogeneity between countries
that offer health insurance coverage and countries that do
not, as well as features that a health system with health
insurance is expected to have. Such features may be better
health planning and improved geographic access.
The country dummies help control for the country effect
and any other regional differences that are not captured by
other variables. Only Argentina, Georgia, Kenya, Malaysia
and Sudan differ from the reference country (Thailand).
This shows how patients are more likely to do in terms of
progress with their disease in different countries. The
effect of occupation is a set of 13 dummy variables show-
ing that skilled workers (business, education, govern-
ment) and the self-employed are significantly more likely
to move to a better health state than less skilled workers
or retirees.
The model results presented in Table 4 relate to all 15
countries; three of these countries account for 78.3% of
the total number of observations (India, 52% of the total
sample; China, 16%; and Pakistan, 10.3%). As a small
number of countries dominate the sample, there may be
potential for bias in the results. In order to account for
this, separate estimations have been produced for India,
China, Pakistan, as well as for the remaining 12 countries
together in order to determine if there are significant dif-
ferences in the results. These are presented in Table 5. The
original phase is statistically significant in all four cases,
and towards the same direction, showing that enrolment
on the program can improve patient outlook (OR>1, α =
1%). Age, gender, the time gap between diagnosis and
approval and whether a patient is closed or not also have
the same effect across all 4 separate regressions. Overall,
the results across the four different models appear to be in
the same direction, and consistent with those in the aggre-
gate sample, suggesting that the factors influencing
patient progress are similar across the countries in the
sample, and that the inclusion of a large number of obser-
vations from just 3 countries does not create a bias.
Survival over time
In total, 3,529 active patients entered GIPAP in the four
quarters of 2005. Figure 1 shows their progress and grad-
ual attrition quarterly over the 2005 - 2007 study period.
Table 6 summarises the number of active patients per
wave and shows the patient attrition on a quarterly basis
as well as the number of active patients remaining at the
end of each quarter. Examining the first wave of patients
during the first quarter of 2005 (Q1 - 2005), a total of 850
active patients entered GIPAP. For these patients, there is
a total of 7,596 observations over the 3-year period (12
quarters), corresponding to an average of 8.94 observa-
tions per patient. Given this natural ceiling, more than 2
years average active period per patient is very high (as
many will carry on being active beyond the study period).
This indicates that for many patients CML becomes a
chronic condition and that those benefiting from imat-
inib are able to return to their activities and in principle
continue to contribute to their families and the local econ-
omy. In Q4 2007 (after 3 years) 520 active patients
Table 4: GIPAP: Results of a Random Effects Ordered Probit 
Model
Dependent Variable Curphase
Odds Ratio SE
Quarter 1.071*** 0.004
Origphase 30.508*** 0.036
Ins 0.989 0.062
Ageatapproval 0.999 0.001
Gender 1.050 0.036
Gap 0.995*** 0.002
Close 0.652*** 0.039
Argentina 3.561*** 0.206
Chile 1.018 0.201
China 1.081 0.098
El Salvador 0.819 0.220
Georgia 2.773*** 0.260
India 1.182 0.098
Kenya 0.285*** 0.263
Malaysia 1.605** 0.187
Mexico 0.880 0.120
Nigeria 0.619* 0.263
Pakistan 0.839 0.109
Russia 0.832 0.154
South Africa 1.010 0.144
Sudan 13.237*** 0.202
Undefined 2.179*** 0.153
Business 1.394*** 0.086
Education 1.330* 0.124
Government 1.259* 0.100
Health-Social 0.931 0.130
Hospitality 1.266 0.177
Manufacturing 1.081 0.079
Other 0.984 0.050
Retired 1.085 0.100
Self Employed 1.247*** 0.068
Student 1.181* 0.094
Transport 1.269 0.221
Unemployed 1.112 0.065
Log Likelihood -19792.852
LR chi2(31) 9836.92
Observations 66,681
Note: Significance levels: *** indicates significance at 1% level; ** at 5% 
level and * at 10% levelGlobalization and Health 2009, 5:19 http://www.globalizationandhealth.com/content/5/1/19
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remain from the first wave. Thus, out of 850 active
patients who started in Q1 2005, 520 were still reported
in the database and were active after 3 years, correspond-
ing to 61.2% of the original patient total. Of the total
number of patients who entered in each quarter of 2005,
at the end of the study period (after 12, 11, 10 and 9 quar-
ters for waves 1, 2, 3 and 4 respectively), in total 2,317
patients remained active in the fourth quarter of 2007,
corresponding to a 66% survival rate.
Figure 2 demonstrates the Kaplan - Meier survival esti-
mates. The Kaplan-Meier survival probability is the frac-
tion of the number of patients surviving in each quarter
over the number of patients at risk. The probability of sur-
viving to any point is estimated from the cumulative prob-
ability of surviving each of the preceding time intervals.
Thus the graph shows the fraction of the population
which survives over time. The four waves are graphed sep-
arately on the same axes, showing how patients in each
wave perform. When comparing survival across the four
waves, the 9-quarter survival ranges between 65.8% (wave
1, covering the period from 2005, Q1, to 2007, Q1) and
72.4% (wave 4, covering the period from 2005, Q4, to
2007, Q4). By the end of the study period (2007, Q4),
66% of all CML patients remain active and are shown to
be receiving treatment under GIPAP. This compares
favourably with the IRIS clinical trial data, despite the dif-
ficulties in delivering care in developing countries. Fur-
ther, many cases are lost track of, indicating that patients
may survive, which would lead to even higher survival
rates (Appendix 1, Note 6).
Discussion & Policy Implications
Access to medicines in developing countries continues to
be adversely affected by poverty and the lack of adequate
statutory health insurance coverage to local populations.
Additional predicaments include the poor state of health
facilities as well as geographical disparities in their availa-
bility, which further hamper patient access. Patients diag-
nosed with CML are no exception to the above problems.
Although treatments such as imatinib are in principle
available on the private market, the out-of-pocket acquisi-
tion cost is prohibitive for most developing country
patients, as the annual drug treatment cost may exceed
$36,000 [17]. Even in cases where a generic version of
branded imatinib becomes available, the out-of-pocket
cost continues to be unaffordable for the vast majority of
patients. Treatment alternatives to imatinib require spe-
cialized care, which may be expensive, not available
within easy reach, and with uncertain outcome.
The findings of the study suggest that patients are signifi-
cantly much more likely to move towards a better health
state after receiving treatment irrespective of their disease
stage at the point of entry to the program and that the
larger the gap between diagnosis and approval for partici-
Table 5: GIPAP: Results of a Random Effects Ordered Probit Model - country breakdown
Country Regressions
Model India China Pakistan Remaining 12 countries
Dependent Variable Curphase Curphase Curphase Curphase
Odds Ratio SE Odds Ratio SE Odds Ratio SE Odds Ratio SE
Quarter 1.069*** 0.006 1.089*** 0.009 0.983 0.015 1.093*** 0.006
Origphase 240.567*** 0.104 21.052*** 0.063 115.816*** 0.165 18.102*** 0.073
Ageatapproval 1.005*** 0.002 0.998 0.002 1.016*** 0.004 0.994*** 0.003
Gender 1.012 0.057 1.021 0.066 1.141 0.106 0.933 0.063
Gap 0.996 0.004 1.001 0.003 0.985** 0.007 0.990*** 0.003
Close 0.685*** 0.086 0.691*** 0.088 0.404*** 0.196 0.694*** 0.059
Log Likelihood -6663.125 -4495.819 -1277.437 -6638.452
LR chi2(31) 4401.33 2278.68 660.41 1612.61
Observations 34,686 10,663 6,837 14,493
Note: Significance levels: *** indicates significance at 1% level; ** at 5% level and * at 10% level.
Active Patients, Waves 1, 2, 3, 4 Figure 1
Active Patients, Waves 1, 2, 3, 4. Source: The authors 
from GIPAP.Globalization and Health 2009, 5:19 http://www.globalizationandhealth.com/content/5/1/19
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pation in the program, the more likely it is that patients'
condition deteriorates due to absence of treatment. Under
the auspices of GIPAP, CML patients are granted free med-
ical treatment, reducing total health costs significantly,
potentially helping patients return to normal activity and
contributing to life extension. This becomes even more
important when taking into account that the average age
of CML patients in developing countries is significantly
lower than that in developed countries [18], suggesting
that GIPAP helps patients in very productive ages. Dem-
onstrating benefit has obvious positive societal implica-
tions for patients and their families in terms of ability to
work and contribution to family income. The 3-year sur-
vival was found to be at minimum 66% of the originally
enrolled patients across the 15 study countries and this
compares favorably with other studies in the developed
world [18]. This is also a strong indication that the pro-
gram provides a sustainable health benefit and that
patients return for their treatment at regular intervals.
The success of GIPAP depends on whether and how
patients' lives are extended by participation in the pro-
gram. If at least two thirds of patients who originally reg-
istered in the program and suffering from this life-
threatening condition are still participating after a 3 year
period, this is a strong indication that the program deliv-
ers care and helps patients stay alive. This rate is likely to
be an underestimate of true overall survival because of the
likely biases in the attrition rate and the number of
patients classified as closed. Because of the definition of
"closure", the attrition rate includes patients who may not
have died and may still be receiving the treatment through
other sources. As a result, the survival rate obtained is the
minimum survival rate of patients in the study period.
GIPAP seems to fulfill the critical role of enabling access
to very poor patients and providing a life-saving treatment
that extends life. Many GIPAP participants go into remis-
sion after receiving imatinib through the program, while
Table 6: GIPAP: 3-year survival for patients entering the programme in 2005
2005 2006 2007
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
Wave 1 (entering quarter 1, 2005)
Active 850 742 701 680 649 626 603 576 559 557 533 520
Not reported/Closed 108 149 170 201 224 247 274 291 293 317 330
Total 850 850 850 850 850 850 850 850 850 850 850 850
Wave 2 (entering quarter 2, 2005)
Active 0 866 752 717 695 655 630 594 574 588 557 537
Not reported/Closed 114 149 171 211 236 272 292 278 309 329
Total 0 866 866 866 866 866 866 866 866 866 866 866
Wave 3 (entering quarter 3, 2005)
Active 0 0 910 795 752 723 704 664 649 639 608 606
Not reported/Closed 115 158 187 206 246 261 271 302 304
Total 0 0 910 910 910 910 910 910 910 910 910 910
Wave 4 (entering quarter 4, 2005)
Active 0 0 0 903 821 775 745 710 695 680 656 654
Not reported/Closed 82 128 158 193 208 223 247 249
Total 0 0 0 903 903 903 903 903 903 903 903 903
All 4 waves (quarters 1 - 4, 2005)
Total Active 850 1608 2363 3095 2917 2779 2682 2544 2477 2464 2354 2317
Total Not reported/Closed 0 108 263 434 612 750 847 985 1052 1065 1175 1212
Total number of patients 850 1716 2626 3529 3529 3529 3529 3529 3529 3529 3529 3529
Source: The authors from GIPAP.Globalization and Health 2009, 5:19 http://www.globalizationandhealth.com/content/5/1/19
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they would otherwise be unable to access the treatment
themselves and face deteriorating health. Participation in
the program is voluntary, and some patients may choose
to drop out; although this is not a desirable outcome, a
patient cannot be prohibited from discontinuing the
treatment, despite the impact this may have on further
patient follow-up, adherence, overall cost and long-term
survival [19].
Close monitoring of patients is critical in order to achieve
the maximum possible adherence and maximize impact.
Given that many patients live in isolated, remote areas,
with limited access to their participating physician or hos-
pital due to distance or unaffordable travel costs, the effec-
tiveness of the program may be adversely affected
compared with a situation where patients have easy access
to health facilities and professionals. This is compatible
with other comparable findings [20] and in order to alle-
viate what seems to be a health problem compounded by
poverty, local governments can assist by improving infra-
structure and communications, in order to maximize the
benefit of programs such as GIPAP.
GIPAP coincides with the appearance and subsequent
proliferation of Global Health Partnerships (GHPs) in the
last decade or so, which have amassed significant support
among bilateral and multilateral donor agencies [9] and
have included product supply initiatives such as the ITI
and the AAI. There are arguments favoring GHPs over
bilateral or multilateral aid, which also apply in the case
of GIPAP and include (a) flexibility in terms of organizing
and delivering care where needed; (b) scale economies;
(c) country links, enabling delivery of care and assistance
in a timely fashion; (d) independence from country-spe-
cific structures as well as donor country preferences; and
(e) their effectiveness in terms of raising and using aid
[21]. As a drug donation scheme, GIPAP must fulfill and
adhere to certain criteria set up by the World Health
Organization on drug donations [22] and good pharma-
ceutical procurement [23].
Drug donation and distribution programs such as GIPAP
may provide an alternative platform for drug access to eli-
gible patients in developing countries. By building on
existing structures in health facilities and mobilizing clini-
cians at no additional cost to local health systems, GIPAP
enables access to a life-saving medication at no cost to
patients or the local health care systems and transforming
a life-threatening disease into a chronic condition. The
distribution of the medicine from the manufacturer to the
patient via the associated NGO provides a practical solu-
tion which also avoids other potential problems associ-
ated with drug donations and distribution channel
shortcomings in both developing and transitional country
contexts. Indeed, evidence suggests that although human-
itarian donations have been an important source of med-
icines for many countries, the donated drugs may not
reach their intended targets, namely the patients [24-26].
Overall, assuming there is continuity in the program over
the long-term, that it is not an opportunistic venture and
that the drug donation segment is compliant with the
WHO guidelines for drug donations, programs such as
GIPAP, resulting from a partnership between different
stakeholders, could provide alternative models of ena-
bling access, providing effective and targeted health care
and making healthcare affordable to patients in develop-
ing countries in the absence of a formal health insurance
coverage system.
The preceding analysis is not without limitations. The
dependent variable is subjective and based on physician
assessment, the latter being subject to time pressure; this
may lead to limitations when examining the factors influ-
encing patient current phase. Additionally, the data do
not record with precision the reason for all "closed" cases.
Although it may not be possible in all developing country
settings to follow all patients, not knowing the precise rea-
son for patient drop-outs can only provide an estimate of
survival analysis. Finally, it may be the case that the results
of the study may not be generalizable to the other coun-
tries that GIPAP covers.
Conclusions
GIPAP has been offering free treatment to CML patients in
developing countries since 2002. This is an example of
patient assistance in countries where very little or no
health insurance or prescription drug coverage exists and
patients cannot afford appropriate treatment. Such initia-
tives can work as a complement to existing public health
insurance schemes and help people fight life-threatening
conditions such as CML.
Survival Analysis (2005 - 2007, quarterly) Figure 2
Survival Analysis (2005 - 2007, quarterly). Kaplan Meier 
Survival Estimates.Globalization and Health 2009, 5:19 http://www.globalizationandhealth.com/content/5/1/19
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We have empirically examined the determinants of
patients' progress in GIPAP. The empirical model has
helped observe the effects of various characteristics on the
phase patients are in and helped detect the differences
across participating countries. The survival analysis
showed that the majority of GIPAP participants remain in
the program for a long time, clearly underlining its effect
on transforming a life-threatening disease into a chronic
one. Access issues are not evident because GIPAP is in
itself a program facilitating access.
Future research could include data from CML patients in
developed countries, and compare the outcomes of treat-
ment of insured patients in developed countries to GIPAP
participants. This would show how the program works
compared to countries with regular health insurance and
would test the possibility of such a patient assistance pro-
gram to act as a substitute for health insurance.
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Appendix 1
Note 1. Imatinib is also used for the treatment of meta-
static malignant gastrointestinal stromal tumors (GIST).
Note 2. In all countries where GIPAP operates, centres are
selected where patients can be offered treatment and be
monitored. The criteria for selecting these centers include
having diagnostic capabilities and having had previous
experience treating CML. In many countries the GIPAP
Qualified Institution is the only institution able to diag-
nose or with the experience to treat CML. This is the case
particularly in many African countries where there is one
cancer center in a single country. However, patients do not
necessarily have to have been diagnosed in GIPAP Quali-
fied Institutions to be offered treatment and enroll onto
the program.
Note 3. TMF has an agreement with each of the GIPAP
physicians and Institutions in all countries it operates. A
Memorandum of Understanding (MOU) between TMF
and each physician is signed upon approval of each phy-
sician as a GIPAP qualified physician. Novartis is not a
formal part of this MOU. On the issue of informed con-
sent, there is a consent form signed by each patient prior
to being approved in GIPAP.
Note 4. Patients with a GIST diagnosis have been excluded
from the analysis.
Note 5. Both "active" and "closed" cases. Closed cases are
subject to review, as patients who may be "closed" on one
occasion may be re-instated subsequently.
Note 6. According to the IRIS clinical trial, estimated rates
of freedom from progression to accelerated phase and
blast phase or overall survival at six years were 61% and
76% respectively.
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